Key Stats for ISRG Stock
- Past week’s performance: -5.3%
- 52-week range: $425 to $604
- Valuation model target price: $717
- Implied upside: 58.5% over 2.8 years
Value your favorite stocks like ISRG with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Intuitive Surgical (ISRG) stock moved lower this week after a regulatory update raised new concerns around product safety. The FDA flagged issues tied to some curved-tip staplers, including reports of injuries and one death. This triggered a recall recommendation, which immediately weighed on investor sentiment.
The market reaction reflects how sensitive high-quality medical device companies are to safety risks. Even though these events are relatively rare, they can affect hospital adoption and regulatory scrutiny. As a result, investors reassessed near-term growth expectations and potential liability risks.
At the same time, insider selling activity throughout March added to the cautious tone. Multiple executives, including the Chief Medical Officer and senior leadership, reported share disposals. While these transactions are not uncommon, they can still influence short-term sentiment.
Importantly, this pullback comes after a strong operational period. The company recently reported Q4 adjusted EPS of $2.53, beating estimates of $2.26. So the stock decline appears driven more by new risks and sentiment shifts rather than any deterioration in underlying demand.
See analysts’ growth forecasts and price targets for ISRG (It’s free) >>>
Is ISRG Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 17.4%
- Operating Margins: 37.4%
- Exit P/E Multiple: 45.1x
Based on these inputs, the model estimates a target price of $717, implying 58.5% total upside from the current share price and a 18.1% annualized return over the next 2.8 years.
The valuation reflects a premium business with strong fundamentals. Intuitive Surgical’s revenue reached $10.1 billion in 2025, growing 20.5% year-over-year. This growth is driven by increasing adoption of robotic-assisted surgery systems and recurring instrument sales.
Margins remain a key strength, with operating margins near 29.3% and gross margins at 66%. The model assumes further expansion to 37.4%, which depends on scale efficiencies and higher procedure volumes. This reflects confidence in the company’s installed base and recurring revenue model.
The current valuation multiple of ~57x earnings is high compared to broader healthcare peers. However, the model assumes a lower exit multiple of 45.1x, suggesting some multiple compression over time. This balances strong growth with normalization in investor expectations.
Overall, the stock appears attractive if execution remains strong. But the premium valuation means any disruption, like regulatory issues, can lead to sharp short-term moves.
What’s Driving the ISRG Stock Going Forward?
The next major catalyst is the upcoming Q1 2026 earnings report expected on April 14. Investors will focus on procedure growth, system placements, and management commentary on the recent FDA issue. Any clarity on the impact of the stapler recall will be critical.
Growth remains driven by expanding surgical adoption globally. The company continues to increase its installed base of da Vinci systems, which drives recurring revenue from instruments and services. This recurring model supports both revenue visibility and margin expansion.
At the same time, recent acquisitions, including the expansion of its distribution business, could enhance international growth. This helps deepen market penetration and supports long-term revenue growth assumptions near 17% annually.
However, regulatory risk and product reliability will remain key watch points. The recent FDA alert shows that even dominant players face operational risks. How management addresses these concerns will likely determine whether the stock regains momentum in the coming months.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Intuitive Surgical, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ISRG, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track ISRG alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Intuitive Surgical stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
